Compare HFFG & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HFFG | ABOS |
|---|---|---|
| Founded | 1997 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.3M | 113.9M |
| IPO Year | N/A | 2021 |
| Metric | HFFG | ABOS |
|---|---|---|
| Price | $2.66 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 79.3K | ★ 151.0K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,225,541,000.00 | N/A |
| Revenue This Year | $4.36 | N/A |
| Revenue Next Year | $3.35 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.10 | N/A |
| 52 Week Low | $1.70 | $0.86 |
| 52 Week High | $4.93 | $2.46 |
| Indicator | HFFG | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 58.01 | 54.90 |
| Support Level | $2.54 | $1.87 |
| Resistance Level | $2.79 | $2.19 |
| Average True Range (ATR) | 0.11 | 0.14 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 62.34 | 68.52 |
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, seafood, frozen and dry food, and non-food products to Asian restaurants and other food service customers throughout the United States. The company's business consists of one operating segment; HF Group, which operates solely in the United States. The company's customer base consists of Chinese and Asian restaurants, and it provides sales and service support to customers who mainly converse in Mandarin or Chinese dialects.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.